Table 1. Meta-analyses reporting generalized symptoms in patients with COVID-19

First author (date of publication) Study period Number of studies/participants Prevalence of symptoms (95% CI)
Groff (Oct 13, 2021) Dec 2019 to Mar 2021 57/250,351 Fatigue or weakness 37.5% (IQR, 25.4% to 54.5%)
Lopez-Leon (Aug 09, 2021) Dec 2019 to Jan 2021 15/47,910 Fatigue 58% (42% to 73%)
Misra (Dec 07, 2021) Dec 2019 to Dec 2020 350/145,721 Fatigue 32%Myalgia 20%Myalgia or fatigue 25 to 37%
Rogers (Jun 3, 2021) Dec 2019 to Jul 2020 147/99,905 Fatigue 37.8% (31.6% to 44.4%)Weakness 40.0% (27.9% to 53.5%)Myalgia 25.1% (19.8% to 31.3%)
Mirmoeeni (Apr 24, 2021) Dec 2019 to Apr 2020 16/4,754 Fatigue 39.27% (30.92% to 47.61%)
Li (Aug 13, 2020) Ja 2020 to Apr 2020 212/281,461 Fever 78.8% (76.2% to 81.3%)Malaise 37.9% (29.5% to 47.1%)
Ahmed (May 08, 2020) Dec 2019 to Mar 2020 13/24,677 Fever 71% (China vs. others 85% vs 53%, p < 0.001)
Kumar (Apr 21, 2020) Jan 2020 to Mar 2020 58/6,892 Fever 83.4% Fatigue 33.8%Association of high fever (>39 °C) and severity: OR 1.59 (1.10 to 2.30)
Manabe (Jun 28, 2020) Dec 2019 to Feb 2020 13/2,397 Fever 82.46% (69.62% to 95.30%)Fatigue 41.11% (25.08% to 57.13%)Myalgia 20.10% (12.08% to 28.11%)
Zhu (Apr 13, 2020) Jan 2020 to Feb 2020 38/3,062 Fever 80.4% (73.0% to 86.9%)Fatigue 46.0% (38.2% to 54.0%)Myalgia 33% (26.0% to 40.5%)
Yang (Mar 12, 2020) Dec 2019 to Feb 2020 7/1,576 Fever 91.3% (86% to 97%)Fatigue 51.0% (34% to 68%)
CI, confidence interval; COVID-19, coronavirus disease 2019; IQR, Interquartile range; OR, odds ratio.